EP3267792A4 - Compositions utilisées pour traiter l'hypertension artérielle pulmonaire - Google Patents

Compositions utilisées pour traiter l'hypertension artérielle pulmonaire Download PDF

Info

Publication number
EP3267792A4
EP3267792A4 EP16762394.1A EP16762394A EP3267792A4 EP 3267792 A4 EP3267792 A4 EP 3267792A4 EP 16762394 A EP16762394 A EP 16762394A EP 3267792 A4 EP3267792 A4 EP 3267792A4
Authority
EP
European Patent Office
Prior art keywords
compositions
arterial hypertension
pulmonary arterial
treating pulmonary
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16762394.1A
Other languages
German (de)
English (en)
Other versions
EP3267792A1 (fr
Inventor
John A. Josey
Eli M. Wallace
Xinlin Du
Barry GOGGIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peloton Therapeutics Inc
Original Assignee
Peloton Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peloton Therapeutics Inc filed Critical Peloton Therapeutics Inc
Publication of EP3267792A1 publication Critical patent/EP3267792A1/fr
Publication of EP3267792A4 publication Critical patent/EP3267792A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP16762394.1A 2015-03-11 2016-03-09 Compositions utilisées pour traiter l'hypertension artérielle pulmonaire Pending EP3267792A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562131783P 2015-03-11 2015-03-11
PCT/US2016/021492 WO2016145032A1 (fr) 2015-03-11 2016-03-09 Compositions utilisées pour traiter l'hypertension artérielle pulmonaire

Publications (2)

Publication Number Publication Date
EP3267792A1 EP3267792A1 (fr) 2018-01-17
EP3267792A4 true EP3267792A4 (fr) 2018-09-26

Family

ID=56879010

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16762394.1A Pending EP3267792A4 (fr) 2015-03-11 2016-03-09 Compositions utilisées pour traiter l'hypertension artérielle pulmonaire

Country Status (3)

Country Link
US (2) US10278942B2 (fr)
EP (1) EP3267792A4 (fr)
WO (1) WO2016145032A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58960B1 (sr) 2013-09-09 2019-08-30 Peloton Therapeutics Inc Aril etri i njihova primena
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016144826A1 (fr) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Pyridines substituées et leurs utilisations
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
WO2016144825A1 (fr) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Composés aromatiques, leurs et utilisations
WO2016168510A1 (fr) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Thérapie combinée avec un inhibiteur de hif-2-alpha et un agent immunothérapeutique, et applications corresponantes
WO2018130174A1 (fr) * 2017-01-11 2018-07-19 江苏豪森药业集团有限公司 Dérivé de pyrrolo[2,3-c]pyridine, son procédé de préparation et son utilisation en médecine
EP3713644A1 (fr) 2017-11-20 2020-09-30 University of Georgia Research Foundation, Inc. Compositions et procédés pour moduler hif-2a afin d'améliorer la production et la réparation des muscles
JP2021519282A (ja) * 2018-03-28 2021-08-10 ペロトン セラピューティクス， インコーポレイテッド ＨＩＦ−２−αの阻害薬による消化器系の炎症軽減方法
WO2019219731A1 (fr) 2018-05-18 2019-11-21 Merck Patent Gmbh Dérivés de thiophène
CN112752761B (zh) 2018-08-21 2024-03-29 杏林制药株式会社 双环杂芳族环衍生物
JP2022500543A (ja) * 2018-09-19 2022-01-04 モデルナティーエックス， インコーポレイテッド 高純度ｐｅｇ脂質及びそれらの使用
CN109796332B (zh) * 2019-03-08 2022-02-11 浙江师范大学 一种2-二氟乙基-1-茚酮衍生物及制备方法
AU2020260130A1 (en) 2019-04-18 2021-11-04 Nikang Therapeutics, Inc. Tetrahydro-1H-cyclopenta(cd)indene derivatives as Hypoxia Inducible Factor-2(alpha) inhibitors
CN112812136B (zh) * 2019-11-15 2022-04-12 武汉光谷亚太医药研究院有限公司 新型2,3-二氢化茚衍生化合物、制备方法和应用
CA3162574A1 (fr) 2019-11-26 2021-06-03 Merck Patent Gmbh Derives de thiophene condenses en tant qu'inhibiteurs du facteur inductible par l'hypoxie (hif)
AU2021240068A1 (en) * 2020-03-19 2022-09-08 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
WO2021212062A1 (fr) 2020-04-16 2021-10-21 Nikang Therapeutics, Inc. Inhibiteurs du facteur-2(alpha) inductible par l'hypoxie et leur utilisation dans le traitement de maladies
US11420936B2 (en) 2020-04-16 2022-08-23 Nikang Therapeutics, Inc. Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases
CN113582968A (zh) * 2020-04-30 2021-11-02 江西济民可信集团有限公司 一类砜亚胺类化合物及其制备方法和应用
EP4166542A1 (fr) * 2020-06-11 2023-04-19 Betta Pharmaceuticals Co., Ltd Composé bicyclique et son application
CN115667190A (zh) * 2020-06-17 2023-01-31 贝达药业股份有限公司 双环类化合物及其应用
CN115667202A (zh) * 2020-06-17 2023-01-31 贝达药业股份有限公司 茚酮类化合物及其应用
WO2022082329A1 (fr) * 2020-10-19 2022-04-28 Nikang Therapeutics, Inc. Procédés de préparation de 3-fluoro-5-(((1s, 2ar)-1, 3, 3, 4, 4-pentafluoro-2a-hydroxy-2, 2a, 3, 4-tétrahydro-1 h-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile
CN112755015A (zh) * 2021-02-01 2021-05-07 中国人民解放军陆军军医大学 Pt2385在制备防治肺动脉高压的药物中的应用
TW202334083A (zh) * 2021-11-02 2023-09-01 大陸商貝達藥業股份有限公司 雙環化合物及其應用
CN115611847B (zh) * 2022-10-13 2024-04-30 南方科技大学坪山生物医药研究院 一种Belzutifan的中间体的制备方法
CN116063211B (zh) * 2023-02-14 2023-11-10 斯坦德药典标准物质研发(湖北)有限公司 一种Belzutifan的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002086497A2 (fr) * 2001-04-24 2002-10-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Utilisation du facteur 2alpha induit par l'hypoxie pour le traitement du syndrome de detresse respiratoire du nouveau-ne et comme cible pour le traitement de l'hypertension pulmonaire
WO2014078479A2 (fr) * 2012-11-14 2014-05-22 The Board Of Regents Of The University Of Texas System Inhibition de l'hétérodimérisation de hif-2α avec hif1β (arnt)

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE705530C (de) 1932-01-23 1941-04-30 Chem Fab Von Heyden Akt Ges Verfahren zur Darstellung von Polychlorsubstitutionsprodukten des Diphenylaethers
FR1574139A (fr) 1968-05-06 1969-07-11
JPS4872169A (fr) 1971-12-28 1973-09-29
GB1448696A (en) 1973-05-29 1976-09-08 Pfizer 2-phqnyl-astriazine-3,4-2h,4h-diones
GB2017087B (en) 1978-03-03 1982-09-02 Roussel Lab Ltd Process for the preparation of xanthone derivatives
US4214103A (en) 1978-11-30 1980-07-22 Great Lakes Chemical Corporation Purification of brominated organic products
DE2938595A1 (de) 1979-09-24 1981-04-23 Celamerck Gmbh & Co Kg, 6507 Ingelheim Verfahren zur herstellung von diphenylaethern
US4505929A (en) 1980-06-12 1985-03-19 The Dow Chemical Company Sulfur-substituted diphenyl ethers having antiviral activity
US4426385A (en) 1980-10-16 1984-01-17 Union Carbide Corporation Insecticidal bicyclooxyphenyl ureas
DE3110894A1 (de) 1981-03-20 1982-09-30 Celamerck Gmbh & Co Kg, 6507 Ingelheim Neue nitroaniline
DE3239449A1 (de) 1981-10-27 1983-05-05 CIBA-GEIGY AG, 4002 Basel Phenoxyphenyl- und pyridyloxyphenyl-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
JPS58124758A (ja) 1982-01-20 1983-07-25 Fujisawa Pharmaceut Co Ltd ベンゼンスルホンアミド誘導体
DE3209878A1 (de) 1982-03-18 1983-09-29 Celamerck Gmbh & Co Kg, 6507 Ingelheim Verfahren zur herstellung von diphenylaethern
US4665097A (en) 1983-03-31 1987-05-12 Union Carbide Corporation Novel bicyclooxyaryl thioureas and process for preparation
US4705955A (en) 1985-04-02 1987-11-10 Curt Mileikowsky Radiation therapy for cancer patients
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
JPS6351363A (ja) 1986-08-21 1988-03-04 Tekukemu:Kk アミノ基を有するジフエニ−ル化合物の製造方法
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US5059609A (en) 1987-10-19 1991-10-22 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases
IL105777A0 (en) 1992-06-04 1993-09-22 Great Lakes Chemical Corp Method for the isolation of a partially brominated diphenyl ether product
DK0640618T3 (da) 1993-08-27 2000-04-03 Hoffmann La Roche Tetrahydronaphthalen-peptidderivater
DE69634639T2 (de) 1995-12-06 2006-03-02 Japan Science And Technology Agency, Kawaguchi Verfahren zur herstellung optische aktive verbindungen
US6887820B1 (en) 1995-12-06 2005-05-03 Japan Science And Technology Corporation Method for producing optically active compounds
CA2283981A1 (fr) 1997-03-20 1998-10-01 Basf Aktiengesellschaft Derives de 2-benz(o)ylpyridines substituees, leur preparation et leur utilisation comme herbicides
ATE309207T1 (de) 1999-08-27 2005-11-15 Sugen Inc Phosphat-mimetika sowie behandlungsmethoden unter verwendung von phosphatase-inhibitoren
CA2473162A1 (fr) 2002-01-30 2003-08-07 Kissei Pharmaceutical Co., Ltd. Nouveau ligand de recepteur de l'hormone thyroidienne, preparations medicinales le contenant et leur utilisation
CA2463464A1 (fr) 2003-04-28 2004-10-28 Auckland Uniservices Limited Methodes de traitement et compositions connexes
SE0301906D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
NZ548128A (en) 2003-12-29 2010-05-28 Banyu Pharma Co Ltd Novel 2-heteroaryl-substituted benzimidazole derivative
EP1749006A2 (fr) 2004-05-28 2007-02-07 Speedel Experimenta AG Composes organiques
WO2006027684A1 (fr) 2004-09-10 2006-03-16 Pfizer Products Inc. Ligands de diphenyl ether therapeutiques
CA2589363A1 (fr) 2004-12-13 2006-06-22 Eli Lilly And Company Derives spiro utilises en tant qu'inhibiteurs de lipoxygenase
AU2006210954A1 (en) 2005-01-31 2006-08-10 Merck & Co., Inc. Antidiabetic bicyclic compounds
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
WO2007045573A1 (fr) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag Phénylacétamides en tant qu'inhibiteurs de nnrt
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
GB0526445D0 (en) 2005-12-23 2006-02-08 Novartis Ag Organic compounds
EP1976828B1 (fr) 2005-12-29 2016-12-21 Celtaxsys, Inc. Dérivés de la diamine utilisés en tant qu'inhibiteurs de la leucotriene a4 hydrolase
BRPI0708347A2 (pt) 2006-02-28 2011-05-24 Cytopia Res Pty Ltd inibição jak2 como um tratamento da hipertensão arterial pulmonar
WO2007099423A1 (fr) 2006-03-02 2007-09-07 Pfizer Products Inc. Dérivés de 1-pyrrolidine indane en tant qu'antagonistes du récepteur d'histamine 3
US20070244071A1 (en) 2006-03-07 2007-10-18 Mount Sinai Hospital Treatment of proliferative diseases
EP2021327B1 (fr) 2006-05-15 2012-04-04 Merck Sharp & Dohme Corp. Composés bicycliques antidiabétiques
ES2399928T3 (es) 2006-08-23 2013-04-04 Neurogen Corporation Análogos de 2-fenoxipirimidinona
BRPI0809483A2 (pt) 2007-03-30 2014-09-09 Nippon Shinyaku Co Ltd Derivados heteroarílicos
CN101058535B (zh) 2007-05-25 2010-07-21 复旦大学 二(7-羟基-2,3-二氢-1-1h-茚基)醚类及其类似物、合成方法及应用
PL2061766T3 (pl) 2007-06-06 2011-02-28 Torrent Pharmaceuticals Ltd Nowe związki
WO2008157273A1 (fr) 2007-06-14 2008-12-24 Smithkline Beecham Corporation Composés chimiques
WO2009093133A1 (fr) 2008-01-25 2009-07-30 Medichem, S.A. Procédé pour déterminer la pureté énantiomérique de dérivés de l'indane
CN101959876A (zh) 2008-03-05 2011-01-26 弗·哈夫曼-拉罗切有限公司 2-氨基喹啉类化合物
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
AR074210A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
US8691866B2 (en) 2008-12-10 2014-04-08 The General Hospital Corporation HIF inhibitors and use thereof
HUE025013T2 (hu) 2009-01-12 2016-04-28 Pfizer Ltd Szulfonamid-származékok
EP2406230A1 (fr) 2009-03-11 2012-01-18 Pfizer Inc. Indazole amides substitués
WO2010137620A1 (fr) 2009-05-27 2010-12-02 武田薬品工業株式会社 Dérivé de phénoxyéthylamine
ES2693687T3 (es) 2009-06-05 2018-12-13 Joan M. Caron Compuestos y composiciones para uso en el tratamiento del cáncer
US8461164B2 (en) 2009-08-31 2013-06-11 Dow Agrosciences, Llc. Pteridines and their use as agrochemicals
EP2493874A1 (fr) 2009-10-30 2012-09-05 Glaxo Group Limited Nouvelles formes cristallines de (3r,6r) -3- (2, 3 -dihydro- 1h- inden- 2 -yl) - 1 - [ (1r) - 1 - (2, 6 - diméthyl - 3 - pyridinyl) - 2 - (4 -morpholinyl) -2-oxoéthyl]-6- [(1s) - 1 -méthylpropyl]-2,5- pipérazinedione
WO2011066537A1 (fr) * 2009-11-30 2011-06-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thérapie au nitroxyde pour le traitement de la maladie de von hippel-lindau (vhl) et d'un hypernéphrome (carcinome des cellules claires rénales (rcc)
JP4902819B1 (ja) 2010-02-26 2012-03-21 株式会社日本触媒 フタロシアニン誘導体
GB201005589D0 (en) 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
JP5787977B2 (ja) 2010-04-08 2015-09-30 レスピバート・リミテツド Ｐ３８ｍａｐキナーゼ阻害剤
WO2011133659A2 (fr) 2010-04-20 2011-10-27 Emory University Inhibiteurs de hif et de l'angiogenèse
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
ES2532357T3 (es) * 2010-07-12 2015-03-26 Pfizer Limited Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor
JP5776691B2 (ja) 2010-07-29 2015-09-09 アステラス製薬株式会社 縮環ピリジン化合物
EP2502917A1 (fr) 2011-03-17 2012-09-26 Santhera Pharmaceuticals (Schweiz) AG Formes cristallines à l'état solide de 4-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-1H-imidazole
CA2837560C (fr) 2011-06-06 2017-02-14 Akebia Therapeutics Inc. Composes et compositions pour la stabilisation du facteur 2 alpha inductible par l'hypoxie comme procede de traitement du cancer
UY34200A (es) 2011-07-21 2013-02-28 Bayer Ip Gmbh 3-(fluorovinil)pirazoles y su uso
US8962608B2 (en) 2011-09-22 2015-02-24 Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
EP2768826A1 (fr) 2011-10-17 2014-08-27 Bayer Intellectual Property GmbH Oxadiazolyl-pyridinones et -pyridazinones substituées servant d'inhibiteurs de hif
BR112014010368A2 (pt) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc biaril éter sulfonamidas e seu uso como agentes terapêuticos
JP2015505542A (ja) 2012-01-28 2015-02-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ アザ複素環式化合物
US9556200B2 (en) 2012-03-06 2017-01-31 Takeda Pharmaceutical Company Limited Tricyclic compound
US9018260B2 (en) 2012-06-21 2015-04-28 Eisai R&D Management Co., Ltd. Indanesulfamide derivatives
EP2888256A4 (fr) 2012-08-24 2016-02-17 Univ Texas Modulateurs hétérocycliques de l'activité du facteur hif utilisés pour le traitement de maladies
EP2888253A4 (fr) 2012-08-24 2016-01-06 Univ Texas Modulateurs hétérocycliques de l'activité du facteur hif utilisés pour le traitement de maladies
US20140128365A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
KR20150088878A (ko) 2012-11-28 2015-08-03 베링거 인겔하임 인터내셔날 게엠베하 신규한 인다닐옥시디하이드로벤조푸라닐아세트산
JP6283862B2 (ja) 2012-12-07 2018-02-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規インダニルオキシジヒドロベンゾフラニル酢酸
EP2981252A4 (fr) 2013-04-04 2017-02-22 Olivia Newton-John Cancer Research Institute Méthodes de traitement de maladies caractérisées par une signalisation wnt excessive
RS58960B1 (sr) 2013-09-09 2019-08-30 Peloton Therapeutics Inc Aril etri i njihova primena
US9884843B2 (en) 2013-12-16 2018-02-06 Peloton Therapeutics, Inc. Cyclic sulfone and sulfoximine analogs and uses thereof
WO2016144826A1 (fr) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Pyridines substituées et leurs utilisations
US10278942B2 (en) * 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016144825A1 (fr) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Composés aromatiques, leurs et utilisations
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
WO2016145236A1 (fr) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Polymorphes d'inhibiteur d'hif-2-alpha
WO2016168510A1 (fr) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Thérapie combinée avec un inhibiteur de hif-2-alpha et un agent immunothérapeutique, et applications corresponantes
US9796697B2 (en) 2015-06-12 2017-10-24 Peloton Therapeutics, Inc. Tricyclic inhibitors of HIF-2-alpha and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002086497A2 (fr) * 2001-04-24 2002-10-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Utilisation du facteur 2alpha induit par l'hypoxie pour le traitement du syndrome de detresse respiratoire du nouveau-ne et comme cible pour le traitement de l'hypertension pulmonaire
WO2014078479A2 (fr) * 2012-11-14 2014-05-22 The Board Of Regents Of The University Of Texas System Inhibition de l'hétérodimérisation de hif-2α avec hif1β (arnt)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AFTAB AHMAD ET AL: "Differential Regulation of Pulmonary Vascular Cell Growth by Hypoxia-Inducible Transcription Factor-1[alpha] and Hypoxia-Inducible Transcription Factor-2[alpha]", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY., vol. 49, no. 1, 1 July 2013 (2013-07-01), NEW YORK, NY, US, pages 78 - 85, XP055499225, ISSN: 1044-1549, DOI: 10.1165/rcmb.2012-0107OC *
D. WENZEL ET AL: "2-Adrenoceptor Antagonist ICI 118,551 Decreases Pulmonary Vascular Tone in Mice via a Gi/o Protein/Nitric Oxide-Coupled Pathway", HYPERTENSION., vol. 54, no. 1, 1 July 2009 (2009-07-01), US, pages 157 - 163, XP055499425, ISSN: 0194-911X, DOI: 10.1161/HYPERTENSIONAHA.109.130468 *
KOEN BRUSSELMANS ET AL: "Heterozygous deficiency of hypoxia-inducible factor-2[alpha] protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia", JOURNAL OF CLINICAL INVESTIGATION, vol. 111, no. 10, 15 May 2003 (2003-05-15), pages 1519 - 1527, XP055499192, ISSN: 0021-9738, DOI: 10.1172/JCI200315496 *
ROGERS JAMIE L ET AL: "Development of Inhibitors of the PAS-B Domain of the HIF-2alpha Transcription Factor", vol. 56, no. 4, 30 January 2013 (2013-01-30), pages 1739 - 1747, XP002738565, ISSN: 0022-2623, Retrieved from the Internet <URL:http://pubs.acs.org/doi/abs/10.1021/jm301847z> [retrieved on 20130130], DOI: 10.1021/JM301847Z *

Also Published As

Publication number Publication date
US20180177754A1 (en) 2018-06-28
US20190015377A1 (en) 2019-01-17
EP3267792A1 (fr) 2018-01-17
WO2016145032A1 (fr) 2016-09-15
US10278942B2 (en) 2019-05-07

Similar Documents

Publication Publication Date Title
EP3267792A4 (fr) Compositions utilisées pour traiter l&#39;hypertension artérielle pulmonaire
EP3496739A4 (fr) Compositions et procédés de traitement de l&#39;hypertension pulmonaire
EP3380199A4 (fr) Dispositif de traitement des cheveux
EP3071215A4 (fr) Compositions et procédés de traitement de l&#39;hypertension pulmonaire
EP3380200A4 (fr) Compositions pour le traitement des cheveux
EP3328414A4 (fr) Composition destinée à être utilisée pour favoriser la cicatrisation de plaies
EP3380062A4 (fr) Compositions pour le traitement des cheveux
EP3380063A4 (fr) Compositions pour le traitement des cheveux
HK1245158A1 (zh) 阿吡莫德組合物及其使用方法
EP3315577A4 (fr) Composition de polissage
EP3242565A4 (fr) Compositions et procédés pour améliorer une performance athlétique
EP3366746A4 (fr) Composition de polissage
EP3296376A4 (fr) Composition de polissage
PL3256589T3 (pl) Kompozycje i sposoby kontrolowania leptinotarsa
SG11201706046PA (en) Polishing composition
EP3366747A4 (fr) Composition de polissage
EP3377105A4 (fr) Compositions pour le traitement de troubles de la calcification ectopique, et méthodes les utilisant
PL3371240T3 (pl) Wodne lakiery bazowe zawierające usieciowane poliuretanowe środki błonotwórcze oraz specjalną kompozycję rozpuszczalników
IL255219A0 (en) pde10 suppressor compounds, preparations containing them and their uses
IL253325A0 (en) Combined treatment of pulmonary hypertension
HK1254371A1 (zh) 粘彈性組合物
EP3532063A4 (fr) Polythérapie pour le traitement de l&#39;hypertension pulmonaire
EP3191447A4 (fr) Composés de s-imino-s-oxo iminothiazine en tant qu&#39;inhibiteurs de bace, compositions, et leur utilisation
GB201513614D0 (en) Compositions, compounds and methods and uses relating thereto
HK1244448A1 (zh) 用於治療肺高血壓的方法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170908

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: JOSEY, JOHN, A.

Inventor name: WALLACE, ELI, M.

Inventor name: GOGGIN, BARRY

Inventor name: DU, XINLIN

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20180824

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/435 20060101ALI20180820BHEP

Ipc: A61K 31/47 20060101ALI20180820BHEP

Ipc: A61K 31/10 20060101ALI20180820BHEP

Ipc: A61K 31/451 20060101ALI20180820BHEP

Ipc: A61K 31/4245 20060101ALI20180820BHEP

Ipc: A61K 31/381 20060101ALI20180820BHEP

Ipc: A61P 9/12 20060101ALI20180820BHEP

Ipc: A61K 31/185 20060101ALI20180820BHEP

Ipc: A61K 31/275 20060101AFI20180820BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190709

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN